Hepatitis B and C diagnosis and treatment guidelines
Transcript of Hepatitis B and C diagnosis and treatment guidelines
Hepatitis B and C diagnosis and treatment guidelines
Philippa Easterbrook Global Hepatitis Programme
.
UNICEF-UNFPA-WHO MEETING WITH MANAFACTURERS AND SUPPLIERS
30 November 2020
Sources – WHO Global Health Estimates
0
0.5
1
1.5
2
2000 2005 2010 2015
Mill
ion
s o
f d
eath
s
Year
Hepatitis Tuberculosis HIV Malaria
1.34 milliondeaths in 2015
96% of the global hepatitis burdenfrom hepatitis B (66%) and C (30%)
Hepatitis silent epidemic, rising mortality
.
due to cirrhosis and hepatocellular carcinoma
Impact of hepatitis B vaccine on prevalence of HBsAg in children under 5 years
Before 2000: 4.7% In 2017:0.8%
257million
900 000deaths
People living with hepatitis B
Global burden of HBV infection
.
Incidence: 1.75 million new infections/yr(Unsafe health care and injection drug use)
Prevalence: 71 million infected, all regions64% burden in 14 countries
Global burden of HCV infection
Sources – WHO (Center for Disease Analysis )Source: WHO Global hepatitis report, 2017
Hepatitis C in Children/Adolescents : 3.5 (3.1-3.9) million infected 19 Countries account for 80% of infections
-
100
200
300
400
500
600
700
800
900
1,000
To
tal
Vir
em
ic In
fecti
on
s (
000)
5
Cascade of care for HCV and HBV infection, WHO region 2016 Major testing and treatment gap
❖Majority of 71 m infected persons remain undiagnosed (80% testing gap)
❖1.76 million started HCV treatment in 2016 and 1.1 million in 2015. (75% treatment gap)
Source – WHO (Center for Disease Analysis )
❖Majority of 257 m infected persons remain undiagnosed (90% testing gap)
❖4.5 million persons were on HBV treatment in 2016 and 1.7 million in 2015. (80% treatment gap)
HBVHCV
6
Progress to date
1. More national strategic plans (93 countries + 43 developing)
2. Achieved price reductions in drugs/ diagnostics (<$100 for HCV cure in 62% countries; Tenofovir<$30/yr)
3. WHO delivered on key global guidance, and Global Reporting process initiated
6. Champion countries moving towards elimination- Egypt: 60m tested and 3.1m treated DAAs: <US$50/cure. Also Georgia,
Mongolia- Pakistan: Launch of Prime Ministers national initiative and micro-elimination
project in Punjab- Australia: “universal ‘treatment access; prisoners and PWID are priority
populations; Nurse prescribing
5. Around 5 m HCV treated and same for HBV
4. On track to achieve 2020 target of >90% HepB3 vaccine. Development of criteria for validation of HBV EMTCT
.
TOPIC RECOMMENDATION
Staging/ non-invasive test (NIT)
▪ APRI preferred NIT to assess for the presence of cirrhosis
Who to treat
▪ Decompensated cirrhosis or cirrhosis (clinical criteria or APRI score >2), regardless of ALT levels, HBeAg, or HBV DNA.
▪ No cirrhosis but persistently abnormal ALT levels +/- ongoing HBV replication, (HBV DNA >20,000 IU/mL or HBeAg +ve).
First line treatment ▪ Drugs with a high barrier to resistance (TDF or ETV ?TAF)
▪ ETV in children aged 2-11 years.
Treatment failure ▪ Switch to TDF if evidence of resistance to 3TC, ETV, ADF, TBV.
Treatment discontinuation
▪ Never discontinue in persons with cirrhosis.
▪ If no cirrhosis, discontinuation on case-by-case basis (persistent HBeAgand/or HBsAg loss or undetectable HBV DNA)
Monitoring (treatment response/toxicity)
▪ On or pre-treatment: ALT + HBV DNA (HBsAg, HBeAg + APRI pre-treatment) annually. More frequent monitoring with cirrhosis.
▪ Assessment of baseline renal function prior to treatment initiation.
Monitoring for HCC ▪ Ultrasound + AFP every 6 months in persons with cirrhosis and/or family history of HCC.
HBV Guideline Recommendations (2015) and planned topics for revisions (2021)
End 2021 CONSOLIDATED HEPATITIS GUIDELINES
Part 4 – HBV –
expanding
eligibility for
treatment and use
of ? TAF
• https://www.who.int/publications/i/item/978-92-4-000270-8
New WHO recommendations on prevention of mother-to child HBV transmissionGuidelines on antiviral prophylaxis in pregnancy (July 2020)
8
.
Triple Elimination of HIV, syphilis and Hepatitis BOpportunity to advance the HBV EMTCT agenda
▪ Triple elimination of HIV, syphilis and HBV
in PAHO and WPRO and now globally
▪Multiple countries developing triple
elimination framework and guidelines
(WPRO/SEARO and PAHO regions)
▪Development of validation criteria for
elimination of viral hepatitis (June and Nov
2020)
.
Updated WHO HCV guidelines (2018)
• Simplified criteria (Who to treat?): HCV treatment for all infected people above 12 years of age (pregnant women excepted)
• Simplified preferred regimens (What to use?): Pan-genotypic regimens (avoid genotyping). Treatment in children and adolescents:
>18 yearsWithout cirrhosis
•Sofosbuvir/Velpatasvir for 12 weeks or•Sofosbuvir/Daclatasvir for 12 weeks or
•Glecaprevir/Pibrentasvir for 8 weeks²
With compensated cirrhosis
•Sofosbuvir/Velpatasvir for 12 weeks or•Glecaprevir/Pibrentasvir for 12 weeks² or
•Sofosbuvir/Daclatasvir for 24 weeks
In adolescents 12-17 years/≥ 35kg⚫ Sofosbuvir/Ledipasvir for 12 weeks in GT 1, 4, 5, 6⚫ Sofosbuvir/Ribavirin for 12 weeks in GT 2⚫ Sofosbuvir/Ribavirin for 24 weeks in GT 3
In children <12 years⚫ Deferring treatment until age 12 years ⚫ Avoiding interferon-based regimens
FOR UPDATE in 2021
• Reconciling DAA
regimens in adult,
adolescents and
children (3-12 years)
treatment
recommendations
• Re-treatment
strategies
.
Topic Recommendation
Who to test? ▪ Focused testing for most affected populations*, those with a clinical suspicion of chronic viral hepatitis, family members/children, and sexual partners (HBV), healthcare workers.
▪ General population testing: In settings with ≥2% or ≥5% (intermediate/high) HBsAg or HCV Ab prevalence.
▪ Birth Cohort testing (HCV): where specific identified birth cohorts of older persons at higher risk of HCV infection
▪ Routine antenatal clinic testing (HBV)
How to test? ▪ A single serological assay (EIA or RDT) that meets minimum performance standardswith prompt NAT testing + linkage to care
Confirmation of HCV viraemia
▪ Nucleic acid testing (NAT) (quantitative or qualitative RNA) or core HCV antigen assay, with comparable clinical sensitivity
Promoting uptake and linkage
▪ Use of DBS specimens for virology ± serology ▪ On-site or immediate RDT testing with same day results▪ Trained peer and lay health workers▪ Clinician reminders to prompt provider initiated, facility-based testing ▪ Testing as part of integrated services at a single facility
Hepatitis testing guideline recommendations 2017
* PWID, people in prisons, MSM, sex workers, HIV-infected, tattoos, transfusions, some migrant pops from endemic
countries, some indigenous populations, children of HBV/HCV +ve mothers
FOR UPDATE in 2021⚫ How to test - serologic
– HCV self-testing -
useablity, acceptability
studies in 5 countries)
– Dried blood spots (HCV
serology and virology)-
Manafacturers protocols
⚫ Confirmation HCV VL
– Use of point of care VL
(5 projects)
– LoD for test of cure
⚫ Linkage to care (completed WHO
systematic review)
– Decentralised HCV test
and treat
– Integrated HCV testing
and treatment at harm
reduction site
– Task-shifting for HCV care
Implement Good Practice Principles for Simplified Service Delivery
1. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis, WHO 2018
1. Simple and standard algorithms across the continuum of care.
2. Strengthening the linkage from testing to care.
3. Integration of hepatitis testing, care and treatment with other
services.
4. Decentralized testing and treatment.
5. Task-shifting to support decentralized care.
6. Engagement with community.
7. Efficient procurement and supply management of quality
medicines and diagnostics.
8. Data systems to monitor the quality of care and coverage
Service delivery in specific populations
• Persons who inject drugs
• People in prisons and other closed settings
• MSM and sex workers
• Adolescents and Children
• Migrant/indigenous populations
• Pregnant women
Moving HCV treatment out of speciality clinics De-centralised testing and treatment “one-stop shops”
PWID
140 studies; 33 countries. High Income countries- 120 (86%), LMIC- 20 (14%)
New WHO Evidence: Full decentralization of testing and treatment increased uptake of testing, linkage and treatment, and achieved comparable SVR12
Lancet Global Health (in press)
Role of Point-of-care viral load in improving linkage
Finger-prick
Minivette capillary tube
Single-use test cartridge
LaptopGeneXpert machine
GeneXpertcartridge
.
Role of HCV self-testing in expanding access to testing
15
HCV self-testing (FIND –WHO -UNITAID)
• Several countries in different geographic regions:• China: Guangdong Center for Skin Disease & STI
Control – MSM population
• Egypt: Egyptian Liver Research Institute and Hospital – General population
• Kenya: UW-Kenya – PWID population
• Georgia: NCDC – general population, MSM, PWID
• Vietnam – community clinic, high risk population
• District hospitals and harm reduction sites
• 100-150 participants per site
• OraQuick HCV rapid diagnostic test modified for self-testing
Integration with other
testing settings or
opportunities eg. HIV,
antenatal or TB
Integrated combo
serology (HIV/HBV/HCV
RDTs), including self-
testing
Build on and integrate
existing multi-disease
platforms (HIV, HCV
RNA and HBV DNA)
HCV care at harm reduction
sites
HIV, HCV and HBV care in
prisons
HCV and HBV care at HIV,
and TB clinics
Opportunities for IntegrationCase Example: Integration of harm reduction with treatment
Through the Medicins du Monde program in Kenya, PWID are able to receive HCV testing and treatment at a drop-in center, promoting a client-centered approach.High retention and adherence are bolstered by• Pre-treatment counselling• Treatment navigation by peer-educators• Psycho-social support
.
• Innovations: Use of PoC viral load, Combo testing, HCV Self-testing, low cost PoC HCV core antigen test, Need WHO PQ for HBeAg RDT for HBV PMTCT, and HBV DNA VL
• Guiding countries on integration with other disease areas and sharing of multidisease platforms
• Gaps in country support for forecasting, drug registration, procurement, price negotiation
• New pricing models (bundled procurement) for diagnostic platforms offer an alternative to traditional procurement contracts
• HCV: Rapid introduction of simplified care model is key
• HBV: Gaps in partner activity
• Treatment indications less clear - expand criteria for treatment (lower APRI score and HBV DNA threshold)
• Simplified care models are needed - integration opportunities with HIV
• No global funder - primarily domestic funding, plus out of pocket costs
Future directions and plans for updated guidelines
End 2021 CONSOLIDATED HEPATITIS GUIDELINES
• Part 1- Service Delivery
and PoC viral load
• Part 2 – HCV DAA
regimens in children and
Re-treatment
• Part 3- HCV self-testing
• Part 4 – HBV – expanding
eligibility for treatment and
use of ? TAF
18
Acknowledgements
WHO Regional office (Antons Mozalevskis, Leandro Sereno, Polin Chan, Fumni Lesi, Joumana Hermez, BB Rewari,)
WHO HQ (Ena Oru, Mark Bulterys, Yvan Hutin, Niklas Luhman, Fuqiang Cui)